Tuesday, April 20, 2021 11:27:05 PM
Yes I admit, I was definitely a big believer in Inmed at one time. But years of the same old run around and absolutely no progress what so ever, nothing but presentations on our dime. Eating at the nicest restaurants and drinking the finest Champagne, staying at the most luxurious Hotels! Complete silence for months! Why does it take half a year or longer to file an application for ph 2 since ph 1 ended? Ridicules. There isn't any interest in Biosynthesis, at least not theirs! I think you're right, the executives are all lining their own pockets and not giving a care in the world about the retail investors! It's too bad!
Recent INM News
- InMed Pharmaceuticals Amends Preferred Investment Options • Newsfile • 04/27/2026 09:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/27/2026 08:58:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/03/2026 08:19:20 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 04/03/2026 08:17:05 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 03/31/2026 04:15:06 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/30/2026 09:37:48 PM
- InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance • Newsfile • 03/27/2026 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/23/2026 11:31:26 AM
- InMed Pharmaceuticals Announces Positive Data from Human Brain Organoid Neuroinflammation Models Supporting the INM-901 Alzheimer's Disease Program • Newsfile • 03/23/2026 11:30:00 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 03/20/2026 09:00:29 PM
- Sidoti Events, LLC's March Small-Cap Virtual Conference • ACCESS Newswire • 03/18/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/09/2026 11:43:44 AM
- InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial • Newsfile • 03/09/2026 11:30:00 AM
- InMed Provides Update on BayMedica Operations and Strengthens Focus on Pharmaceutical Development Pipeline • Newsfile • 03/06/2026 10:04:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2026 09:58:07 PM
- InMed Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update • Newsfile • 02/11/2026 10:23:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/11/2026 10:04:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2025 04:42:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2025 04:42:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2025 04:42:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2025 04:41:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2025 04:41:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/18/2025 04:55:06 PM
- InMed Announces Results of 2025 Annual General and Special Meeting • Newsfile • 12/18/2025 01:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/17/2025 05:20:20 PM
